

IRADIMED CORP  
Form 8-K  
December 22, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **December 22, 2014**

**IRADIMED CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**001-36534**  
(Commission File Number)

**73-1408526**  
(IRS Employer Identification No.)

**1025 Willa Springs Dr., Winter Springs, FL**  
(Address of Principal Executive Offices)

**32708**  
(Zip Code)

**(407) 677-8022**

Edgar Filing: IRADIMED CORP - Form 8-K

(Registrant's Telephone Number, Including Area Code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01**                      **Regulation FD Disclosure.**

On December 22, 2014, IRADIMED CORPORATION issued a press release announcing that it had resumed domestic shipment of its MRI compatible MRidium 3860 IV infusion pump systems. A copy of the press release is attached hereto as *Exhibit 99.1* and incorporated herein by reference.

**Item 9.01**                      **Financial Statements and Exhibits.**

(d)                      Exhibits

<b>Exhibit No.</b>	<b>Document</b>
99.1	Press Release dated December 22, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IRADIMED CORPORATION**

Date: December 22, 2014

By:	/s/ Chris Scott
Name:	Chris Scott
Title:	Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Document</b>
99.1	Press Release dated December 22, 2014